Replies to post #391833 on Anavex Life Sciences Corp (AVXL)

[sokol]

“The ANAVEX®2-73 Phase 2b/3 study design incorporates genomic precision medicine biomarkers identified in the ANAVEX®2-73 Phase 2a study.”

https://www.anavex.com/press-releases/first-patient-enrolled-in-anavex-life-sciences-phase-2b%2F3-clinical-trial-of-anavex%C2%AE2-73-for-the-treatment-of-early-alzheimer%E2%80%99s-disease

[Steady_T]

And the conclusion one may draw from the fact that Anavex hasn't run a precision medicine trail so far, in spite of attempting to identify numerous candidates as being biomarkers, is that it hasn't needed to resort to precision medicine.
The results so far have been broad enough that limiting a trial population based on precision medicine selection has not been required to obtain significance.

That is a big positive.